June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Cyclopentolate 1% Decreases Schlemm’s Canal Dimension in Normal Subjects
Author Affiliations & Notes
  • Michael Rosman
    Moise and Chella Safra Advanced Ocular Imaging Laboratory, Einhorn Clinical Research Center, New York Eye and Ear Infirmary of Mount Sinai, New York, NY
  • Alon Skaat
    Moise and Chella Safra Advanced Ocular Imaging Laboratory, Einhorn Clinical Research Center, New York Eye and Ear Infirmary of Mount Sinai, New York, NY
  • Sung Chul Park
    Moise and Chella Safra Advanced Ocular Imaging Laboratory, Einhorn Clinical Research Center, New York Eye and Ear Infirmary of Mount Sinai, New York, NY
    Department of Ophthalmology, Manhattan Eye, Ear and Throat Hospital, Hofstra North Shore-LIJ School of Medicine, New York, NY
  • Jason L Chien
    Moise and Chella Safra Advanced Ocular Imaging Laboratory, Einhorn Clinical Research Center, New York Eye and Ear Infirmary of Mount Sinai, New York, NY
  • Mark Ghassibi
    Moise and Chella Safra Advanced Ocular Imaging Laboratory, Einhorn Clinical Research Center, New York Eye and Ear Infirmary of Mount Sinai, New York, NY
  • Siddarth Rathi
    Moise and Chella Safra Advanced Ocular Imaging Laboratory, Einhorn Clinical Research Center, New York Eye and Ear Infirmary of Mount Sinai, New York, NY
  • Robert Ritch
    Moise and Chella Safra Advanced Ocular Imaging Laboratory, Einhorn Clinical Research Center, New York Eye and Ear Infirmary of Mount Sinai, New York, NY
  • Jeffrey M Liebmann
    Harkness Eye Institute, Columbia University Medical Center, New York, NY
  • Footnotes
    Commercial Relationships Michael Rosman, None; Alon Skaat, None; Sung Chul Park, Heidelberg Engineering, GmbH (R); Jason Chien, None; Mark Ghassibi, None; Siddarth Rathi, None; Robert Ritch, None; Jeffrey Liebmann, Carl Zeiss Meditech, Inc. (F), Heidelberg Engineering, GmbH (C), Heidelberg Engineering, GmbH (F), Optovue, Inc. (F), Topcon, Inc. (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4986. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Michael Rosman, Alon Skaat, Sung Chul Park, Jason L Chien, Mark Ghassibi, Siddarth Rathi, Robert Ritch, Jeffrey M Liebmann; Cyclopentolate 1% Decreases Schlemm’s Canal Dimension in Normal Subjects. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4986.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To characterize the in vivo effect of cyclopentolate 1%, an anticholinergic agent, on the structure of Schlemm’s canal (SC) in normal eyes.

Methods: Healthy subjects with no ocular or systemic diseases known to affect the iridocorneal angle or trabecular aqueous outflow structures were prospectively recruited. Eighty-one serial horizontal enhanced depth imaging (EDI) optical coherence tomography (OCT) B-scans (interval between B-scans, ~35 µm) of the nasal corneoscleral limbal area were obtained before and 1 hour after cyclopentolate 1% administration. With conjunctival vessels and iris anatomy as landmarks, the same limbal area was scanned before and after cyclopentolate administration. The SC cross-sectional area was measured in each selected EDI OCT B-scan. After three-dimensional reconstruction, SC volume was determined.

Results: Eight eyes (5 men, 3 women; mean age, 27±4 years) were included. Mean intraocular pressure was 13.4±1.3 mmHg before and 13.8±1.1 mmHg after cyclopentolate administration (p=0.17). All patients developed mydriasis after administration. Schlemm’s canal was continuous in the scanned area in all eyes and was successfully delineated and reconstructed 3-dimensionally pre- and post cyclopentolate administration. Mean SC cross-sectional area decreased after cyclopentolate administration (6855±658µm2 vs. 5848±791µm2; p<0.01). Mean SC volume also decreased (11852607±1145016 µm3 vs. 10117350±1368343 µm3; p<0.01).

Conclusions: Cyclopentolate 1% decreases SC dimension in healthy subjects. Whether this results from a direct anticholinergic effect on the canal or secondarily from its effect on the ciliary musculature and/or decreased trabecular outflow remains to be determined. EDI OCT of Schlemm’s canal may prove useful in evaluating the mechanisms of action of pharmacologic agents in glaucoma.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×